Active replication — ongoing trial, registry, or meta-analysis.
The cardiovascular benefit of icosapent ethyl observed in REDUCE-IT is attributable to mechanisms beyond triglyceride lowering alone, given the magnitude of risk reduction exceeds what triglyceride reduction alone would predict.
TL;DR · AI-generated
Among patients with elevated triglyceride levels despite the use of statins, the risk of ischemic events, including cardiovascular death, was significantly lower among those who received 2 g of icosapent ethyl twice daily than amongThose who received placebo.
Author-implied confidence
60%
Live consensus
Status
DRAFT
Your position — does this noeme still stand given current evidence?
0% (impossible)
50%
100% (certain)
Proper-scoring-rule preview
Your position is kept on this device until you sign in.
Evidence stream
1 event · 1 snapshot
posterior drift
79% → 79% (0pp · 1 point)
Peer-reviewed paper
Apr 18, 2026
Expert reactions · 0
Sign in to post a take, cite a related claim, or flag a methodological concern.
No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.
Source publication
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
· openalex W2899669642 · s2 eaa96eb4
Semantically related
Nearest claims in the expert-corpus vector space. Ordered by cosine distance — lower is closer.
0.1466
Icosapent ethyl 4 g daily reduces the key secondary composite endpoint of cardiovascular death, nonfatal MI, or nonfatal stroke by 26% (HR 0.74) compared to placebo in statin-treated patients with elevated triglycerides.
0.1467
Icosapent ethyl 4 g daily significantly reduces cardiovascular mortality (4.3% vs. 5.2%; HR 0.80) compared to placebo in statin-treated patients with elevated triglycerides.
0.1482
Icosapent ethyl 4 g daily reduces the composite primary endpoint of cardiovascular death, nonfatal MI, nonfatal stroke, coronary revascularization, or unstable angina by 25% (HR 0.75) compared to placebo in statin-treated patients with elevated triglycerides over a median 4.9-year follow-up.
0.1702
The cardiovascular benefit of icosapent ethyl will not be replicated by other omega-3 fatty acid formulations containing DHA in addition to EPA at comparable doses.
0.2312
Icosapent ethyl 4 g daily is associated with a significantly higher rate of hospitalization for atrial fibrillation or flutter (3.1% vs. 2.1%) compared to placebo in statin-treated patients with elevated triglycerides.
0.2430
The absolute cardiovascular benefit of alirocumab over placebo is greater in post-ACS patients with a baseline LDL cholesterol of 100 mg/dL or higher compared to those with lower baseline LDL levels.